NFKB1 and Parkinson disease: The administration of hypoestoxide could reduce neuroinflammation, neurodegeneration, and α-syn accumulation in a mouse model of PD via modulating the activity of NF-κB, suggesting that hypoestoxide may be a potent anti-PD drug (Kim et al., 2015).